Ultragenyx Pharmaceutical (RARE) Q2 2024 earnings summary

Executive summary

• Q2 2024 total revenue reached $147 million, up 36% year-over-year, driven by strong growth in Crysvita, Dojolvi, and Evkeeza sales, with robust demand across commercial therapies and successful product launches in multiple regions.

• Four approved products across five indications in ten years, with the largest clinical pipeline in rare disease and rapid development timelines averaging 5.5 years from clinic to approval.

• Significant clinical progress with positive data readouts and regulatory milestones for late-stage programs, including UX111, GTX102, DTX401, and UX143, with pivotal studies and regulatory filings expected in late 2024 and 2025.

• Raised 2024 total revenue guidance to $530–$550 million, reflecting increased global demand and strong product performance.

• Ongoing expense management and revenue growth support a path to profitability by 2026.

Financial highlights

• Q2 2024 product sales were $147 million, with Crysvita contributing $114 million, Dojolvi $19 million, Evkeeza $8 million, and Mepsevii $6 million.

• Net loss for Q2 2024 was $132 million ($1.52 per share), an improvement from $160 million ($2.25 per share) in Q2 2023.

• Cash, cash equivalents, and marketable securities totaled $874 million as of June 30, 2024, including $381 million from a June offering.

• Operating expenses for Q2 2024 were $263 million, including $162 million R&D, $81 million SG&A, and $21 million cost of sales.

• Net cash used in operations was $77 million for Q2 and $268 million for the first half of 2024.

Outlook and guidance

• 2024 total revenue guidance raised to $530–$550 million, with Crysvita expected at the upper end of $375–$400 million and Dojolvi at $75–$80 million.

• Net cash used in operations for 2024 expected to be less than $400 million.

• Revenue growth and expense management expected to drive profitability by 2026.

• Multiple significant product approvals and key clinical catalysts anticipated in late 2024 and 2025.

• Annual operating expenses anticipated to remain stable or decrease as cost management continues.